Dipeptidyl peptidase-4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes

Background: There are concerns that dipeptidyl deptidase-4 (DPP-4) inhibitors, second- to third-line antidiabetic drugs, may be linked to the development of bullous pemphigoid, a rare but potentially severe autoimmune blistering skin condition. To address these concerns, we conducted a population-based study to determine whether the use of DPP-4 inhibitors, when compared with the use of other second- to third-line antidiabetic drugs, is associated with an increased risk of bullous pemphigoid in patients with type 2 diabetes.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research